SNGX stock: Invest for short term more than 3 months less than six months

 I like to look into investment of SNGX stock. 

Dr. Schaber continued, "With approximately $20 million of cash and our non-dilutive government funding, we will evaluate strategic options as we continue to execute on the multiple development programs across our rare disease pipeline. Most importantly, this will include the preparation of a New Drug Application for SGX301 in the treatment of cutaneous T-cell lymphoma, which demonstrated statistical significance in its pivotal Phase 3 clinical trial earlier this year, as well as continuing activities towards SGX301 U.S. commercialization where we expect peak annual sales to exceed $75 million."

• Soligenix (NASDAQ:SNGX) plunges 44% premarket in reaction to the announcement of preliminary top-line results for its Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity) trial evaluating SGX942 (dusquetide) in the treatment of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) receiving chemoradiation.

Actionable Items

I plan to purchase 300 shares of SNGX, and if it continues to drop more than 20%, then I will purchase at most 100 shares. 

I like to see what will happen about the business.